Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 9:05 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1513–1536 of 10,730 matching trials from the live ClinicalTrials.gov search.
Conditions
Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Stage I Chronic Lymphocytic Leukemia, Stage I Small Lymphocytic Lymphoma, Stage II Chronic Lymphocytic Leukemia, Stage II Small Lymphocytic Lymphoma, Stage III Chronic Lymphocytic Leukemia, Stage III Small Lymphocytic Lymphoma, Stage IV Chronic Lymphocytic Leukemia, Stage IV Small Lymphocytic Lymphoma
Interventions
Alvocidib Hydrochloride, Cyclophosphamide, Diagnostic Laboratory Biomarker Analysis, Pharmacological Study, Rituximab
Drug · Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Myelodysplastic Syndrome
Interventions
Vosaroxin
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
New York, New York
Conditions
AML
Interventions
Obatoclax
Drug
Lead sponsor
Gemin X
Industry
Eligibility
70 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
12
States / cities
Chicago, Illinois • Iowa City, Iowa • Westwood, Kansas + 8 more
Conditions
Lymphoma, Malignant Solid Neoplasm, Plasma Cell Myeloma
Interventions
Xisomab 3G3
Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Multiple Myeloma
Interventions
Belantamab mafodotin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
8
States / cities
Tucson, Arizona • Beverly Hills, California • Plantation, Florida + 5 more
Conditions
Lymphoma, Infection, Leukemia
Interventions
Fluconazole, Voriconazole
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
2 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
33
States / cities
Birmingham, Alabama • La Jolla, California • Stanford, California + 25 more
Conditions
Hemophilia A
Interventions
FVIII concentrate
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
Not listed
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
13
States / cities
Atlanta, Georgia • Indianapolis, Indiana • Lexington, Kentucky + 9 more
Conditions
Acute Myelogenous Leukemia, Acute Lymphoid Leukemia, Juvenile Myelomonocytic Leukemia, Myelodysplastic Syndrome
Interventions
azacitidine, donor lymphocyte infusion
Drug · Biological
Lead sponsor
University of California, San Francisco
Other
Eligibility
Up to 29 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
San Francisco, California
Conditions
11q-deleted Relapsed/Refractory Chronic Lymphocytic Leukaemia (CLL),, Prolymphocytic Leukaemia (PLL), B Cell Lymphomas
Interventions
Administration of AZD6738
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
La Jolla, California
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interventions
ASTX727
Drug
Lead sponsor
Taiho Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Houston, Texas
Conditions
Sickle Cell Disease, Vaso-Occlusive Pain Episode in Sickle Cell Disease, Ketamine Infusion, Pain Management, Vaso-Occlusive Crises
Interventions
Sub-dissociative Ketamine Infusion, Normal Saline Placebo Infusion
Drug
Lead sponsor
Mohsen Saidinejad
Other
Eligibility
5 Years to 20 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Torrance, California
Conditions
Leukemia
Interventions
recombinant flt3 ligand
Biological
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
47
States / cities
Birmingham, Alabama • La Jolla, California • San Francisco, California + 29 more
Conditions
Blasts Under 15 Percent of Bone Marrow Nucleated Cells, Blasts Under 15 Percent of Peripheral Blood White Cells, Blasts Under 30 Percent of Bone Marrow Nucleated Cells, Blasts Under 30 Percent of Peripheral Blood White Cells, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Interventions
Bosutinib, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Houston, Texas
Conditions
Acute Myelocytic Leukemia, Acute Lymphocytic Leukemia, Chronic Myelocytic Leukemia, Chronic Lymphocytic Leukemia, Myelodysplastic Syndromes
Interventions
ON 01910.Na
Drug
Lead sponsor
Traws Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
New York, New York
Conditions
Leukemia
Interventions
Busulfan, Fludarabine, Clofarabine, Total Body Irradiation (TBI), Thymoglobulin, Stem Cell Infusion, Cyclophosphamide, Tacrolimus, Mycophenolate mofetil, Decitabine, Cytarabine, Idarubicin
Drug · Radiation · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 60 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Houston, Texas
Conditions
Acute Myelogenous Leukemia, Acute Lymphatic Leukemia, Chronic Myelogenous Leukemia, Myelodysplastic Syndromes, Myelodysplastic Syndrome Other, Chronic Myelomonocytic Leukemia, Lymphoma, Hodgkin Lymphoma
Interventions
Cyclophosphamide, Fludarabine, Thiotepa, Total Body Irradiation, Double Umbilical Cord Transplant, Tacrolimus, Mycophenolate Mofetil, Abatacept
Drug · Radiation · Biological
Lead sponsor
Leland Metheny
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Cleveland, Ohio
Recruiting No phase listed Observational Accepts healthy volunteers

Pre-malignant States to Hematologic Malignancies in Firefighters

NCT06870760
Conditions
Clonal Hematopoiesis of Indeterminate Potential, Monoclonal Gammopathy, Non Hodgkin Lymphoma, Leukemia, Multiple Myeloma, Plasma Cell Disorder
Interventions
Monoclonal Gammopathy, Complete Blood Count with differential (CBC w/ diff), Clonal hematopoiesis (CHIP)
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
40 Years to 49 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Charlotte, North Carolina
Conditions
Viral Disease, Blood Donation, Transfusion-Transmitted Infections
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Not listed
Enrollment
1,771 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Conditions
Paroxysmal Nocturnal Hemoglobinuria, PNH
Interventions
Danicopan
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Cancer, Survivorship, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions
SHARE-S Implementation Program
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 100 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Conditions
Healthy Participants, Hemophilia A, Hemophilia B, Factor VII Deficiency
Interventions
SR604, Placebo
Drug
Lead sponsor
Equilibra Bioscience LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
9
States / cities
Glendale, California • Los Angeles, California • Chicago, Illinois + 6 more
Conditions
Acute Myelogenous Leukemia
Interventions
CD3-/CD19- natural killer cells, CD3-CD56+ natural killer cells, CliniMACS® CD3 and CD19 Reagent System, CliniMACS® CD56 Reagent System, Cyclophosphamide, Fludarabine, Aldesleukin
Biological · Device · Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
2
States / cities
Minneapolis, Minnesota • St Louis, Missouri
Conditions
Relapsed/Refractory Multiple Myeloma
Interventions
Dose Escalation, MEDI2228, ADC (antibody drug conjugate), Dose Expansion, MEDI2228, ADC (antibody drug conjugate)
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 101 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
8
States / cities
Phoenix, Arizona • Jacksonville, Florida • Boston, Massachusetts + 4 more
Conditions
Hematologic Diseases
Interventions
20-19 Tan BB06oz CAR T
Biological
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
12 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Buffalo, New York